| 1/4 | US=9 / Urologia Sissung TM, Figg WD. Clinical pharmacology and pharmacogenetics of chemotherapy in prostate cancer. In: Figg WD, Chau CH, Small EJ. Drug management of prostate cancer. New York: Springer - Verlag, 2010. p. 163-77. ISBN 978-1-60327-831-7. FARMACOGENETICA DA QUIMIOTERAPIA. CANCER DE PROSTATA; FARMACOLOGIA CLINICA; DOCETAXEL; MITOXANTRONA; ESTRAMUSTINA; SATRAPLATIN; CANCER DE PROSTATA; FARMACOGENETICA; FARMACOLOGIA |
| 3/4 | US=16 / Urologia Mohile SG, Petrylak DP. Therapeutics: taxane-based chemotherapy for prostate cancer. In: Chung LWK, Isaacs WB, Simons JW. Prostate cancer: biology, genetics, and the new therapeutics. 2ª ed. New Jersey: Humana Press, 2007. p. 445-62. (Contemporary Cancer Research) ISBN 978-1-58829-696-2. CANCER DE PROSTATA; TERAPEUTICA; TAXANO; QUIMIOTERAPIA; DOCETAXEL; ESTRAMUSTINA; PACLITAXEL; PALIACAO; RESISTENCIA; SOBREVIVENCIA; TAXANO |
| 4/4 | US=120 / Câncer Machado KK, Braghirotti MI, Rêgo JFM, Hoff PMG. Agentes antimicrotúbulos. In: Hoff PMG. Tratado de oncologia. São Paulo: Atheneu, 2013. p. 767-777. ISBN 85-388-0312-6. ALCALOIDES DA VINCA; TAXANO; DOCETAXEL; FOSFATO DE ESTRAMUSTINA; EPOTILONAS |